Literature DB >> 7128664

Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man.

S A Johansson, K E Andersson, R Brattsand, E Gruvstad, P Hedner.   

Abstract

Topical anti-inflammatory (cutaneous "vasoconstriction") and systemic glucocorticoid (depression of plasma cortisol and changes in differential WBC count) potencies of the two glucocorticoids budesonide and beclomethasone dipropionate (BDP) were compared in human volunteers. After topical application, budesonide was 2-3 times more potent than BDP in inducing "vasoconstriction". After oral administration, on the other hand, budesonide was 2-4 times less potent than BDP in depressing plasma cortisol and changing the total or differential WBC. After inhalation, too, significant differences in favour of budesonide were noted, but the divergence between the drugs was less pronounced. The improved relationship between the topical and systemic glucocorticoid effects of budesonide makes it a promising alternative for aerosol treatment in asthma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7128664     DOI: 10.1007/bf00609625

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  20 in total

1.  Pharmacokinetic studies of a potent glucocorticoid (budesonide) in dogs by high-performance liquid chromatography.

Authors:  A Ryrfeldt; M Tönnesson; E Nilsson; A Wikby
Journal:  J Steroid Biochem       Date:  1979-03       Impact factor: 4.292

2.  Absorption and metabolism of orally administered beclomethsone dipropionate.

Authors:  L E Martin; R J Tanner; T J Clark; G M Cochrane
Journal:  Clin Pharmacol Ther       Date:  1974-03       Impact factor: 6.875

3.  Methodological aspects on clinical trials with inhaled corticosteroids: results of two comparisons between two steroid aerosols in patients with asthma.

Authors:  J Björkander; H Formgren; S A Johansson; E Millqvist
Journal:  Eur J Respir Dis Suppl       Date:  1982

4.  Comparison between inhaled and oral corticosteroids in patients with chronic asthma.

Authors:  L Rosenhall; G Lundqvist; E Adelroth; C Glennow
Journal:  Eur J Respir Dis Suppl       Date:  1982

5.  Minimum dose requirements of steroid-dependent asthmatic patients for aerosol beclomethasone and oral prednisone.

Authors:  J H Toogood; N M Lefcoe; D S Haines; L Chuang; B Jennings; N Errington; L Baksh; M Cauchi
Journal:  J Allergy Clin Immunol       Date:  1978-06       Impact factor: 10.793

6.  Beclomethasone dipropionate steriod aerosol in treatment of perennial allergic asthma in children.

Authors:  H M Brown; G Storey
Journal:  Br Med J       Date:  1973-07-21

7.  Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma.

Authors:  R Wyatt; J Waschek; M Weinberger; B Sherman
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245

8.  Effect on plasma cortisol level and urinary cortisol excretion, in healthy volunteers, after application of three different topical steroid ointments under occlusion.

Authors:  M Scott; L A Malmsten; I Thelin
Journal:  Acta Derm Venereol       Date:  1981       Impact factor: 4.437

9.  Influence of 16 alpha, 17 alpha-acetal substitution and steroid nucleus fluorination on the topical to systemic activity ratio of glucocorticoids.

Authors:  R Brattsand; A Thalén; K Roempke; L Källström; E Gruvstad
Journal:  J Steroid Biochem       Date:  1982-06       Impact factor: 4.292

10.  Absorption and metabolism of intratracheally instilled cortisol and beclomethasone dipropionate in the isolated perfused rat lungs.

Authors:  J Hartiala; P Uotila; W Nienstedt
Journal:  Med Biol       Date:  1979-10
View more
  23 in total

1.  The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler.

Authors:  S Pedersen; G Steffensen; S V Ohlsson
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

Review 2.  The place of high-dose inhaled corticosteroids in asthma therapy.

Authors:  M J Smith
Journal:  Drugs       Date:  1987-05       Impact factor: 9.546

3.  Systemic effects of inhaled corticosteroids.

Authors:  J P Monson
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

Review 4.  New perspectives on inhaled drug delivery and systemic bioactivity.

Authors:  B J Lipworth
Journal:  Thorax       Date:  1995-02       Impact factor: 9.139

5.  Beclomethasone-induced vasoconstriction in women with major depressive disorder.

Authors:  Nick J Coupland; Kathleen M Hegadoren; Jessica Myrholm
Journal:  J Psychiatry Neurosci       Date:  2003-09       Impact factor: 6.186

Review 6.  Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

7.  Dysphonia caused by inhaled steroids: recognition of a characteristic laryngeal abnormality.

Authors:  A J Williams; M S Baghat; D E Stableforth; R M Cayton; P M Shenoi; C Skinner
Journal:  Thorax       Date:  1983-11       Impact factor: 9.139

8.  Inhaled budesonide fails to inhibit the PAF-induced increase in plasma leukotriene B4 in man.

Authors:  M M Nieminen; E K Moilanen; M O Koskinen; J I Karvonen; L Tuomisto; T J Metsä-Ketelä; H Vapaatalo
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects.

Authors:  P H Brown; S P Matusiewicz; C Shearing; L Tibi; A P Greening; G K Crompton
Journal:  Thorax       Date:  1993-10       Impact factor: 9.139

10.  Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate.

Authors:  N H Birkebaek; G Esberg; K Andersen; O Wolthers; C Hassager
Journal:  Arch Dis Child       Date:  1995-12       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.